



# Corrigendum: Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte Apoptosis via Nrf2/HO-1 Pathway

Xiaowan Wang<sup>1,2,3,4†</sup>, Jinchu Liu<sup>1,2†</sup>, Ruimin Tian<sup>1,2,3,4†</sup>, Bidan Zheng<sup>1</sup>, Chuang Li<sup>1,2,3,4</sup>, Lihua Huang<sup>1,2,3,4</sup>, Zhisheng Lu<sup>1,2</sup>, Jing Zhang<sup>1,4</sup>, Wei Mao<sup>1,2,3,4</sup>, Bo Liu<sup>1,4,5\*</sup>, Kun Bao<sup>1,2,3,4\*</sup> and Peng Xu<sup>1,2,3,4\*</sup>

<sup>1</sup>State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, <sup>2</sup>Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, <sup>3</sup>Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou, China, <sup>4</sup>Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China, <sup>5</sup>Guangzhou Key Laboratory of Chirality Research on Active Components of Traditional Chinese Medicine, Guangzhou, China

## OPEN ACCESS

### Edited and reviewed by:

Adolfo Andrade-Cetto,  
National Autonomous University of  
Mexico, Mexico

### \*Correspondence:

Peng Xu  
xupeng@gzucm.edu.cn  
Kun Bao  
baokun@aliyun.com  
Bo Liu  
doctliu@gzucm.edu.cn

<sup>†</sup>These authors have contributed  
equally to this work and share first  
authorship

### Specialty section:

This article was submitted to  
Ethnopharmacology,  
a section of the journal  
Frontiers in Pharmacology

Received: 27 March 2022

Accepted: 05 April 2022

Published: 27 April 2022

### Citation:

Wang X, Liu J, Tian R, Zheng B, Li C,  
Huang L, Lu Z, Zhang J, Mao W, Liu B,  
Bao K and Xu P (2022) Corrigendum:  
Sanqi Oral Solution Mitigates  
Proteinuria in Rat Passive Heymann  
Nephritis and Blocks Podocyte  
Apoptosis via Nrf2/HO-1 Pathway.  
*Front. Pharmacol.* 13:905693.  
doi: 10.3389/fphar.2022.905693

**Keywords:** Sanqi oral solution, passive Heymann nephritis, podocyte apoptosis, proteinuria, Nrf2/ HO-1 signaling pathway

## A Corrigendum on

### Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte Apoptosis via Nrf2/HO-1 Pathway

by Wang, X., Liu, J., Tian, R., Zheng, B., Li, C., Huang, L., Lu, Z., Zhang, J., Mao, W., Liu, B., Bao, K. and Xu, P. (2021). *Front. Pharmacol.* 12:727874. doi: 10.3389/fphar.2021.727874

In the original article, there was an error. The concentration units of Sanqi oral solution lyophilized power (SQL) and doxorubicin hydrochloride (ADR) in cell experiment were incorrectly written as “600 mg/ml and 400 µg/ml.” It should be “600 µg/ml and 400 ng/ml.”



A correction has been made to **Materials and Methods, Podocyte Culture and Treatment, Paragraph 1:**

“The conditionally immortalized temperature sensitive mouse podocyte cell line used in this study was established by Professor Peter Mundel (Medical College of Harvard University, Boston, MA, United States). Briefly, podocytes were cultured in RPMI 1640 medium with 10% fetal bovine serum at 33°C in the presence of 10 U/ml recombinant mouse interferon-γ (Sigma, St. Louis, MO, United States). For inducing differentiation, podocytes were thermoshifted to 37°C and cultured in interferon-free medium for 10–14 days. SQL and Trig were dissolved in PBS and storage solutions were stored at –20°C. Podocytes were cultured overnight before experiments and treated with 400 ng/ml ADR with or without 25 µM Nrf2 inhibitor Trig or 600 µg/ml SQL intervention for 24 h.”

In the original article, there was a mistake in the labels of **Figures 7, 8** as published. The concentration unit of SQL in cell experiment should be 600 µg/ml, not 600 mg/ml. The corrected **Figures 7, 8** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



Copyright © 2022 Wang, Liu, Tian, Zheng, Li, Huang, Lu, Zhang, Mao, Liu, Bao and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s)

and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.